For years, researchers have known that untreated hearing loss is one of the most significant modifiable risk factors for dementia. The 2020 report of the Lancet Commission on dementia estimated that hearing loss in midlife accounts for about 8% of dementia cases worldwide. But "we know it's linked" and "we know why" are two very different things. A September 2026 secondary analysis of the landmark ACHIEVE randomized controlled trial, published in eClinicalMedicine, has taken a small step toward answering the second question. In 164 trial participants, hearing treatment was linked to a slower rise in a blood marker of brain inflammation. If you or someone you love has been putting off hearing aids, it's worth understanding what this means.
What the ACHIEVE Trial Found About Hearing Aids and Brain Health
The ACHIEVE trial was a large, well-designed randomized controlled trial that followed older adults aged 70–84 with untreated hearing loss. Participants were randomly assigned either to receive hearing aids along with audiological counseling, or to a health education control group. In the main trial of 977 people, the hearing intervention did not slow cognitive decline overall, but it appeared to slow it in a higher-risk group recruited from a long-running heart health study. This new secondary analysis looked at blood samples from 164 people in that higher-risk group.
Specifically, researchers tracked GFAP (glial fibrillary acidic protein), a biomarker that rises in the blood when there's neuroinflammation or stress on the brain's support cells. Over three years, GFAP naturally increased in both groups, as it tends to do with aging. But the hearing intervention group showed a significantly slower rise in GFAP compared to controls. In other words, hearing treatment was linked to a slower rise in a blood marker of brain inflammation. The authors call GFAP a non-specific marker, note that the group was small, and say the result needs to be repeated in larger studies. A second marker, NfL, which reflects damage to nerve cells, also rose more slowly with hearing treatment, but that difference was not statistically significant.
A blood marker can hint at what is happening in the brain, but this result does not show that hearing aids prevent dementia.
Why Neuroinflammation Is Worth Taking Seriously
GFAP isn't a household name yet, but it's increasingly showing up in Alzheimer's and dementia research. When the brain is under stress (from injury, disease, or chronic sensory deprivation), the glial cells that support neurons become activated. They release GFAP into the bloodstream. Elevated GFAP has been associated with Alzheimer's pathology, cognitive decline, and faster brain aging.
The leading theory connecting hearing loss to brain inflammation goes something like this: when the auditory system is chronically deprived of input, the brain works harder to process degraded signals. That sustained cognitive effort, sometimes called "listening fatigue," may contribute to chronic stress on brain tissue. Over years and decades, that stress accumulates. Hearing aids, by delivering cleaner sound signals, may reduce that burden and, in turn, slow the inflammatory cascade. This small study fits that theory but does not prove it.
Who Benefits Most, and the Numbers That Caught Researchers' Attention
Not everyone with hearing loss benefits equally from intervention, which is part of why the ACHIEVE trial has generated so many follow-up analyses. A 2025 secondary analysis of the ACHIEVE data found that older adults with multiple risk factors for cognitive decline who received a hearing intervention experienced up to 61.6% slower three-year cognitive decline compared to controls. For people who already have cardiovascular risk factors, a family history of dementia, or other markers of elevated risk, treating hearing loss may bring more benefit than it does for people at lower risk.
The picture from a separate large-scale study adds more texture. A 2026 analysis published in Neurology using data from the ASPREE trial found that hearing aid use was linked to a meaningfully lower risk of developing dementia, even though it didn't significantly improve scores on standard cognitive tests. Over 7 years, the estimated dementia risk was 5.0% for people who got a new hearing aid prescription and 7.5% for those who did not. This was an observational analysis, not a randomized test of hearing aids, and the authors say they cannot rule out other differences between the groups as the explanation. That gap (lower dementia risk without better test scores) suggests that hearing aids may protect the brain through pathways that routine cognitive assessments don't measure well. GFAP may be one of those pathways.
The public health stakes are significant. Hearing loss affects about 65% of adults over 60, according to the ACHIEVE researchers, and the FDA says only about one-fifth of people who could benefit from a hearing aid seek help. Some hold back because of cost, some because of stigma, some because they've been told "your hearing isn't bad enough yet." That last message may deserve a rethink.
The Gap Between Who Needs Hearing Aids and Who Has Them
Hearing aid adoption remains stubbornly low. Even after the FDA created a new over-the-counter hearing aid category for adults 18 and older with perceived mild to moderate hearing loss, which took effect on October 17, 2022, most older adults with clinically significant hearing loss still don't use amplification. The reasons are understandable: the devices can feel conspicuous, they require adjustment, and some people don't notice how much they've been missing until they try them.
But the research trajectory is shifting the conversation from "quality of life" to "brain health." That reframe tends to motivate people differently. Struggling to follow a dinner table conversation feels like a social inconvenience. Learning that the same untreated hearing loss may be measurably accelerating neuroinflammation in your brain feels far more urgent.
Video: Mayo Clinic Minute: How hearing issues may affect brain health -- Mayo Clinic
What Hearing Aids and Brain Health Research Means for Your Next Steps
You don't need to wait for your annual physical to take this seriously. The evidence suggests you can do the following right now:
Get a hearing evaluation if you haven't recently. Many audiologists offer baseline assessments. Over-the-counter hearing aids can be bought in a store or online without a prescription or a hearing test, but the FDA says they are only for adults 18 and older with perceived mild to moderate hearing loss, not severe or profound loss. The FDA advises seeing a doctor, preferably an ear, nose and throat specialist, if your hearing changed suddenly in the past 6 months, is worse in one ear, or you have ear pain, fluid coming from the ear, or dizziness. If you're 60 or older and haven't had a hearing test in the past few years, schedule one. Think of it the way you think of getting your blood pressure checked.
Don't wait until hearing loss is "severe." The ACHIEVE trial enrolled adults with untreated hearing loss measured at 30 to 70 decibels in the better ear, not only those with profound impairment. Whether treating hearing loss earlier protects the brain has not been tested.
Track your overall health picture alongside hearing. Hearing loss rarely travels alone: it tends to co-occur with cardiovascular risk factors, poor sleep, and reduced physical activity, all of which also affect brain health. If you use SteadiDay Premium, the app's Apple Health integration lets you bring together data from your activity, sleep, and other health metrics in one place, so you can see how your habits are stacking up across the domains that matter most for aging well.
Talk to your doctor about your individual risk profile. If you have other risk factors for cognitive decline (high blood pressure, diabetes, a sedentary lifestyle, family history of dementia), the case for treating hearing loss proactively becomes even stronger. Bring the ACHIEVE research to the conversation if you need to. This is exactly the kind of evidence your doctor should know about.
Don't let stigma make the decision for you. Hearing aids have changed considerably in the past decade. Many are now small, Bluetooth-enabled, and rechargeable. The visible-hearing-aid stigma is a social calculation worth revisiting.
The Bigger Picture on Brain Protection
No single intervention prevents dementia. But the science of dementia prevention increasingly looks like a collection of modifiable factors (sleep, exercise, blood pressure control, social connection, hearing), each contributing a meaningful slice. Hearing loss is on that list, but the evidence that treating it prevents dementia is still limited: ACHIEVE did not slow cognitive decline overall, and the biomarker results come from a small group.
The brain is remarkably adaptive, but it's not infinitely forgiving. Years of chronic sensory deprivation leave a mark. The encouraging finding from this research is that intervention, even later in life and even with hearing aids, appears to slow that mark from deepening. It isn't a cure, but it's something concrete you can act on, starting this week.
Common Questions
Can hearing aids reduce the risk of dementia, or only slow cognitive decline?
Neither has been proven. In the ACHIEVE trial, the hearing intervention did not slow cognitive decline overall, though it appeared to in a higher-risk group. A 2026 observational analysis of ASPREE study data found that hearing aid use was linked to a lower risk of dementia, but it could not rule out other explanations, and its authors say long-term trials are needed. The new ACHIEVE biomarker research, in 164 people, found a slower rise in GFAP, a blood protein linked to brain inflammation.
What is GFAP and why does it matter for brain health?
GFAP stands for glial fibrillary acidic protein. It's released into the bloodstream when the brain's support cells become stressed or inflamed, a process associated with Alzheimer's disease and other forms of neurodegeneration. Elevated GFAP levels are increasingly used in research as an early biomarker of brain stress. In 164 ACHIEVE participants at higher risk of dementia, those who got hearing treatment had a slower rise in GFAP over three years than those who did not. GFAP is a non-specific marker, so this hints at, but does not prove, less brain inflammation.
My hearing loss is mild. Is it worth getting hearing aids at this stage?
The ACHIEVE trial included adults with untreated hearing loss measured at 30 to 70 decibels in the better ear, so it was not limited to severe impairment. Whether treating mild hearing loss earlier protects the brain has not been tested. A hearing evaluation is a low-risk first step: it tells you where you stand and gives you and your doctor the information needed to make an informed decision.
Are over-the-counter hearing aids as effective as prescription devices for brain health?
The research so far doesn't draw a firm distinction between OTC and prescription devices in terms of brain health outcomes; the ACHIEVE trial used prescription hearing aids with audiological support. OTC hearing aids, sold in the U.S. since October 2022, are only for adults 18 and older with perceived mild to moderate hearing loss, not severe or profound loss, and can be a more affordable entry point. For more significant hearing loss, or if you try OTC devices and don't notice improvement, seeing an audiologist for a fitted prescription device is worth the investment.
Updated November 15, 2026: We made clear that the ACHIEVE blood marker results come from 164 people, that GFAP is a non-specific marker, and that the main ACHIEVE trial did not slow cognitive decline overall. We noted that the ASPREE analysis was observational, dated the Lancet Commission's 8% estimate to its 2020 report, replaced an unsourced hearing loss statistic, and added the FDA's rules for over-the-counter hearing aids: adults 18 and older with perceived mild to moderate hearing loss, and when to see a doctor first. We also removed claims that hearing aids are proven to protect the brain.
Sources
This article draws on the sources below. Each entry shows the passage it supports.
- PubMed Central: “2020 report of the Lancet Commission on dementia”
- PubMed: “main trial of 977 people”
- PubMed Central: “hearing treatment was linked to a slower rise in a blood marker of brain inflammation”
- PubMed Central: “2025 secondary analysis of the ACHIEVE data found that older adults with multiple risk factors for cognitive decline who received a hearing intervention experienced up to 61.6% slower three-year cognitive decline”
- PubMed Central: “A 2026 analysis published in Neurology using data from the ASPREE trial found that hearing aid use was linked to a meaningfully lower risk of developing dementia”
- PubMed Central: “ACHIEVE researchers”
- FDA: “the FDA says”
SteadiDay for iPhone
Emergency SOS, fall detection and medication reminders are free, with no card to enter. Premium adds Share Activity for caregivers, Apple Health and the wellness tools.
Download on the App Store